Monoclonal Anti-Influenza Virus H5 Hemagglutinin (HA) Protein (VN04-10), A/Vietnam/1203/2004 (H5N1), (ascites, Mouse)

Catalog No. NR-2737

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

Rockland Immunochemicals Inc.

Product Description:

Antibody Class: IgG2bκ

Mouse monoclonal antibody specific to a recombinant form of the H5 hemagglutinin (HA) protein (GenPept: AAT73274) of the A/Vietnam/1203/2004 (H5N1) strain of influenza virus was produced in mouse ascites.[1,2] Ascites formation was induced by injecting cultured hybridoma cells into the peritoneal cavity of BALB/c mice that had been primed with Incomplete Freund's adjuvant.[3] Antibody-rich ascites fluid was aseptically harvested 1 to 2 weeks following hybridoma cell injection. The harvested ascites fluid was pooled and then clarified using centrifugation and filtration. Sodium azide (0.02%) and gentamycin (0.01%) were added to the pooled ascites fluid prior to vialing and lyophilization.

HA is an antigenic glycoprotein found on the surface of the influenza A virus that is responsible for binding of the virus to receptors on a cell that is being infected.[4,5] Following receptor binding, the influenza A virus can enter the cell via endocytosis and membrane fusion. H5 HA is associated with the pathogenicity of the deadly H5N1 avian influenza A virus because it readily undergoes proteolytic cleavage into an active form that is necessary for viral entry into cells.[6] As a result, HA is an important target for drug and vaccine development.[7,8]

Material Provided:

Each vial of NR-2737 contains lyophilized (0.2 mL containing 0.02% sodium azide and 0.01% gentamycin) mouse ascites fluid.

Packaging/Storage:

NR-2737 was packaged in glass serum vials with an aluminum crimp seal. The product is provided frozen and should be stored at -20°C to -40°C immediately upon arrival. Storage at warmer temperatures is not recommended due to a low bioburden. At colder temperatures, the rubber stopper may become brittle and compromise the seal. NR-2737 should be reconstituted with 0.2 mL of sterile distilled water. Reconstituted material should be stored at -20°C to -40°C. Reconstituted material may be thawed at room temperature and should be re-frozen.

Functional Activity:

NR-2737 is specific for the H5 HA subtype of the influenza A virus as determined in standard hemagglutination inhibition (HI) assays. NR-2737 also demonstrates high reactivity within the H5 HA subtype of recent Asian isolates of influenza A virus based on HI assays.

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Influenza Virus H5 Hemagglutinin (HA) Protein (VN04-10), A/Vietnam/1203/2004 (H5N1), (ascites, Mouse), NR-2737."

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Guan, Y., et al. "H5N1 Influenza: A Protean Pandemic Threat." Proc. Natl. Acad. Sci. U.S.A. 101 (2004): 8156–8161. PubMed: 15148370.
2. Li, K. S., et al. "Genesis of a Highly Pathogenic and Potentially Pandemic H5N1 Influenza Virus in Eastern Asia." Nature 430 (2004): 209–213. PubMed: 15241415. GenPept: AAT73274.
3. Mueller, U. W., C. S. Hawes, and W. R. Jones. "Monoclonal Antibody Production by Hybridoma Growth in Freund's Adjuvant Primed Mice." J. Immunol. Methods 87 (1986): 193–196. PubMed: 3950429.
4. Skehel, J. J. and D. C. Wiley. "Receptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin." Annu. Rev. Biochem. 69 (2000): 531–569. PubMed: 10966468.
5. Stevens, J., et al. "Structure and Receptor Specificity of the Hemagglutinin from an H5N1 Influenza Virus." Science 312 (2006): 404–410. PubMed: 16543414.
6. Hatta, M., P. Gao, P. Halfmann, and Y. Kawaoka. "Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses." Science 293 (2001): 1840–1842. PubMed: 11546875.
7. Hoffmann, E., et al. "Role of Specific Hemagglutinin Amino Acids in the Immunogenicity and Protection of H5N1 Influenza Virus Vaccines." Proc. Natl. Acad. Sci. U.S.A. 102 (2005): 12915–12920. PubMed: 16118277.
8. Govorkova, E. A., et al. "Immunization with Reverse-Genetics-Produced H5N1 Influenza Vaccine Protects Ferrets Against Homologous and Heterologous Challenge." J. Infect. Dis. 194 (2006): 159–167. PubMed: 16779721.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898